Research notes

EBO has posted its FY26 results and FY27 guidance, which were in line with consensus (Visible Alpha). The result was achieved despite higher fuel costs and FX headwinds and resulted in a ~10% jump in the share price. After a capital-intensive few years, management is asking the market and investors to look forward to the business returning to EPS growth from FY28. We have made modest changes to forecasts. Our target price is now A$22.93 (previously A$22.92). We maintain our Buy recommendation.

It was a challenging year for STP, following a significant pricing and promotional reset, which impacted sales and earnings. STP reported FY26 revenue down 27% to $63.7m, and reported a $1.7m EBITDA profit excluding the $9.1m inventory obsolescence provision. Our valuation lowers in line with earnings revisions in outer years, and lower peer multiples. We retain our HOLD recommendation with a $0.16 price target.

2Q26 delivered record revenue, a second FY26 guidance upgrade, and net cash burn nearly halved QoQ, the clearest balance sheet de-risking since the cost reset. PermeaDerm-I hit its primary endpoint (70% cheaper than allograft, comparable healing). Small study, but a useful lead indicator for Cohealyx/RECELL cross-sell. The two updates support a more positive view on execution and portfolio breadth, though cash remains thin enough and debt balance big enough to keep a cautious stance. Our target price rises to A$2.20 p/s but given the share price rally, we move to a SELL recommendation. Happy to let the share price settle at current levels.

HUB’s FY26 Group result was largely in line with expectations with underlying EBITDA of A$211.4m, up 30% on pcp, consistent with MorgansF/Consensus A$212m, and underlying NPAT of A$137.3m slightly ahead of MorgansF A$131.9m. Platform EBITDA however fell short of expectations due to slower revenue momentum in 2H26, which was outpaced by 2H26 Platform Opex growth. HUB’s FY28 FUA target of A$186-200bn points to FY28 net flows of ~A$18-19bn, however momentum through to Aug’26 appears to be running behind this due to elevated discretionary gross outflows. Whilst the timing of this roll-off remains uncertain, we see this as a near-term headwind and likely to abate, although it does suggest FY27 flows will track lower than FY26 (particularly vs. 1H26). Our EPS forecast moves by +/-1% in FY27-28F, which sees our price target revised to A$92.00/sh. We retain our Accumulate rating.

The Tallebung PFS outlines a capital-efficient, high-margin tin-tungsten-silver project with a base-case pre-tax NPV8 of A$438m and pre-tax IRR of 69% (US$45,000/t Sn, US$1,500/mtu WO3, US$50/oz Ag). The PFS mine plan draws on only ~66% of the current 32.7Mt Resource by tonnes and ~42% of contained tin, leaving significant scope for reserve conversion and mine-life extensions ahead of the DFS. Upside is further supported by deliberately conservative tungsten and silver recovery and payability assumptions. Following an analyst change, we maintain our SPECULATIVE BUY rating and raise our price target to A$0.40 per share (previously A$0.35).

A solid FY26 result, with an upsized final dividend of US 99cps, against a share price that appears to already factor in more upside, we lower our rating to TRIM. Metal prices were a key driver, but BHP also maintained a solid operating performance on controllable factors against a tough backdrop in FY26.

FY26 PBT landed towards the top end of the revised guidance range and FY27 guidance was reaffirmed offering strong earnings growth. EPS forecasts moderated 2-6%. Target price reduced 5 cps to $1.42/sh. BUY retained, with c.33% potential TSR at current prices.

The FY26 result was broadly in line with expectations, with revenue of US$15.8bn (+3% vs guidance) and underlying NPATA of US$3.1bn. Importantly, underlying Ig demand remains strong, Seqirus delivered seasonal influenza growth despite lower US immunisation rates and transformation savings reached US$176m ahead of target, although Vifor continues to face challenges. While FY27 targets flat top line growth, as Vifor remains a significant drag, the earnings trajectory is becoming increasingly skewed towards recovery, supported by stabilising plasma economics, cost-outs and improved commercial execution. We make modest changes to FY27-28 estimates and increase our blended DCF, PE and EV/EBITDA-based target price to A$187.71 on a multiple roll forward. BUY.

SRG delivered a strong FY26 with EPSA growth of +30%, largely consistent with its 5-year EPSA CAGR of +32%. FY27 guidance was upgraded, and the momentum looks set to continue. Organic growth is strong (2H EBITA +19%) and the order book has risen sharply (+20% in 6 months), providing robust visibility into FY27 and beyond. We increase our target price to $4.70 (from $4.20). Although SRG has re-rated, earnings momentum via organic and inorganic growth could see the company continue to compound +30% EPS growth over the next 3 years. BUY.

With FY27 guidance (6 cpu distribution) issued and an updated NTA ($1.35/sh), the FY26 result goes some way to de-risking HCW. However, a return to stabilised FFO (ps) and cash-covered distributions is likely slower than anticipated (FFO guidance at =4 cpu vs distributions at 6 cpu), and contingent on a progressive ramp up in UHF distributions over time. HCW is trading on an 8% distribution yield and a 47% discount to NTA - clearly attractive metrics. Offsetting this, HCW will be overdistributing while the UHF fund de-levers (UHF gearing at 43%), and subsequently investors should expect HCW’s cash payout ratio to trend down from 1.5x towards <1.0 in FY30, with an underlying payout ratio c.100%. We reiterate our SPECULATIVE BUY, PT $0.85/sh.